Evidence map›Paper›PMID 16342411›Full record

ArticleMolecular and cellular biochemistry2005

B23 is a downstream target of polyamine-modulated CK2.

Kathryn Lawson, Laura Larentowicz, Lisa Laury-Kleintop, Susan K Gilmour

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kathryn LawsonLankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.
Laura Larentowicz
Lisa Laury-Kleintop
Susan K Gilmour
Lankenau Institute for Medical Research · US

Funding

POLYAMINES AND EPITHELIAL TUMORIGENESISR01CA070739 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI GILMOUR, SUSAN K. · 1996 to 2010
$2.8M
IN VIVO MODULATION OF PROTEIN KINASE CK2 BY POLYAMINESR01CA076664 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI GILMOUR, SUSAN K. · 1998 to 2002
$663k
NCI NIH HHS CA070739NCI NIH HHS CA76664
6 · The paper itself

Abstract

Our previous studies have shown that the overexpression of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis, increases the enzymatic activity of the polyamine-responsive enzyme casein kinase 2 (CK2). Because CK2 is known to preferentially associate with the nuclear matrix in response to other trophic stimuli, we investigated the effects of ODC overexpression on CK2 localisation and on the CK2-mediated phosphorylation of a known CK2 substrate, the nucleolar phosphoprotein B23. Immunofluorescence analysis of CK2 and B23 in primary keratinocytes revealed that ODC overexpression resulted in the colocalisation of CK2 with B23 at the nucleolar borders. ODC overexpression also increased CK2 kinase activity 2-fold at the nuclear matrix, a response which could be abrogated by treatment of K6/ODC transgenic keratinocytes with the ODC inhibitor alpha-difluoromethylornithine (DFMO). Levels of B23 protein were also elevated in ODC-overexpressing cells compared to normal cells or transgenic cells treated with DFMO. This increase in protein level was neither due to an increase in steady-state mRNA levels, nor was it due to increased stability of B23 protein. Phosphorylation of B23 was also increased in ODC-overexpressing cells, and this increased phosphorylation could be blocked by treatment of the cells with the CK2 kinase inhibitors apigenin or 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB). These data suggest that B23 may be a downstream effector of polyamines via phosphorylation by the protein kinase CK2.

Indexed as

Signal TransductionAnimalsApigeninCasein Kinase IICell NucleolusCells, CulturedDichlororibofuranosylbenzimidazoleEflornithineKeratinocytesMiceMice, TransgenicNuclear MatrixNuclear ProteinsNucleophosminOrnithine DecarboxylaseOrnithine Decarboxylase InhibitorsApigeninCasein Kinase IIDichlororibofuranosylbenzimidazoleEflornithineNpm1 protein, mouseNuclear ProteinsNucleophosminOrnithine DecarboxylaseOrnithine Decarboxylase InhibitorsPolyamines

Identifiers

PMID16342411
OpenAlexW2086601894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.